Spinal Muscular Atrophy
Summary
Clinical characteristics.
Spinal muscular atrophy (SMA) is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal > distal, and progressive. Before the genetic basis of SMA was understood, it was classified into clinical subtypes based on maximum motor function achieved; however, it is now apparent that the phenotype of SMN1-associated SMA spans a continuum without clear delineation of subtypes. With supportive care only, poor weight gain with growth failure, restrictive lung disease, scoliosis, and joint contractures are common complications; however, newly available targeted treatment options are changing the natural history of this disease.
Diagnosis/testing.
The diagnosis of SMA is established in a proband with a history of motor difficulties or regression, proximal muscle weakness, reduced/absent deep tendon reflexes, evidence of motor unit disease, AND/OR by the identification of biallelic pathogenic variants in SMN1 on molecular genetic testing. Increases in SMN2 copy number often modify the phenotype.
Management.
Treatment of manifestations: Therapies targeted to the underlying disease mechanism include nusinersen (Spinraza®; an antisense oligonucleotide) for the treatment of all types of SMA and onasemnogene abeparvovec-xioi (Zolgensma®; gene replacement therapy) for the treatment of type I SMA. These targeted treatments may prevent the development or slow the progression of some features of SMA; efficacy is improved when treatment is initiated before symptom onset. It is unclear what the long-term effect of these treatments will be or if new phenotypes will arise in treated individuals.
Proactive supportive treatment by a multidisciplinary team is essential to reduce symptom severity, particularly in the most severe cases of SMA. When nutrition or dysphagia is a concern, placement of a gastrostomy tube early in the course of the disease is appropriate. Standard therapy for gastroesophageal reflux disease and chronic constipation. Formal consultation and frequent follow up with a pulmonologist familiar with SMA is necessary. As respiratory function deteriorates, tracheotomy or noninvasive respiratory support may be offered. Surgical repair for scoliosis should be considered based on progression of the curvature, pulmonary function, and bone maturity. Surgical intervention for hip dislocation for those with pain.
Surveillance: Presymptomatic individuals require monitoring for the development of symptoms to determine appropriate timing to initiate targeted and/or supportive therapies. Multidisciplinary evaluation every six months or more frequently for weaker children is indicated to assess nutritional state, respiratory function, motor function, and orthopedic status, and to determine appropriate interventions.
Agents/circumstances to avoid: Prolonged fasting, particularly in the acutely ill infant with SMA.
Evaluation of relatives at risk: It is appropriate to determine the genetic status of younger, apparently asymptomatic sibs of an affected individual in order to identify as early as possible those who would benefit from prompt initiation of targeted treatment.
Genetic counseling.
SMA is inherited in an autosomal recessive manner. Each pregnancy of a couple who have had a child with SMA has an approximately 25% chance of producing an affected child, an approximately 50% chance of producing an asymptomatic carrier, and an approximately 25% chance of producing an unaffected child who is not a carrier. These recurrence risks deviate slightly from the norm for autosomal recessive inheritance because about 2% of affected individuals have a de novo SMN1 variant on one allele; in these instances, only one parent is a carrier of an SMN1 variant, and thus the sibs are not at increased risk for SMA. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the diagnosis of SMA has been confirmed by molecular genetic testing in an affected family member.
Diagnosis
A consensus document on the diagnosis of children with SMA was initially developed by Wang et al [2007] and was updated by Mercuri et al [2018] (see Establishing the Diagnosis).
Suggestive Findings
Scenario 1. Abnormal newborn screening (NBS) result
- NBS for spinal muscular atrophy (SMA) is primarily based on real-time PCR that detects the common SMN1 deletion and may also detect SMN2 copy number on dried blood spots [Chien et al 2017].
- Follow-up molecular genetic testing confirmation of a positive NBS result is recommended (see Establishing the Diagnosis).
Scenario 2. Symptomatic individual who has EITHER atypical findings associated with later-onset SMA OR infantile-onset SMA that has not been treated (either because NBS was not performed or because it yielded a false negative result)
- History of motor difficulties, especially with loss of skills
- Proximal > distal muscle weakness
- Hypotonia
- Areflexia/hyporeflexia
- Tongue fasciculations
- Hand tremor
- Recurrent lower respiratory tract infections or severe bronchiolitis in the first few months of life
- Evidence of motor unit disease on electromyogram
Establishing the Diagnosis
The diagnosis of SMA is established in a proband with a history of motor difficulties or regression, proximal muscle weakness, reduced/absent deep tendon reflexes, and evidence of motor unit disease; AND/OR by identification of biallelic pathogenic variants in SMN1 on molecular genetic testing (see Table 1). Increases in SMN2 copy number often modify the phenotype.
Molecular Genetic Testing Approaches
Scenario 1. Abnormal newborn screening (NBS) result
When NBS results suggest the diagnosis of SMA, confirmatory molecular genetic testing typically includes single-gene testing. Gene-targeted deletion/duplication analysis to determine the dosage of SMN1 is performed first for the SMN1 exon 7. If one copy of SMN1 exon 7 is present, perform sequence analysis of SMN1. If exon 7 is present in both copies of SMN1, consider other diagnoses (see Differential Diagnosis).
Because SMN1 sequence analysis cannot determine whether a putative inactivating variant is in SMN1 or SMN2 (see Molecular Genetics), one of the following is required to confirm that the variant is present in SMN1:
- Establish that the inactivating variant has previously been reported in SMN1; OR
- Sequence a long-range PCR product or a subclone of SMN1.
Note: Gene-targeted deletion/duplication analysis to determine SMN2 copy number can be performed to provide additional information for clinical correlation if the diagnosis of SMA is confirmed on molecular genetic testing (see Genotype-Phenotype Correlations).
See Figure 1 for a summary of the diagnostic algorithm for SMA as published by Mercuri et al [2018].

Figure 1.
Diagnostic algorithm for SMA
Scenario 2. A symptomatic individual with findings associated with later-onset SMA or untreated infantile-onset SMA (resulting from NBS not performed or false negative NBS result)
Molecular genetic testing approaches can include single-gene testing (see above) or use of a multigene panel that includes SMN1, SMN2, and other genes of interest (see Differential Diagnosis). Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests. For this disorder a multigene panel that also includes deletion/duplication analysis is recommended (see Table 1).
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.
Table 1.
Molecular Genetic Testing Used in Spinal Muscular Atrophy
| Type of Testing | Gene 1 | Proportion of SMA Attributed to Pathogenic Variants in Gene | Proportion of Pathogenic Variants 2 Detectable by Method | |
|---|---|---|---|---|
| Sequence analysis 3 | Gene-targeted deletion/ duplication analysis 4 | |||
| Diagnostic, carrier, prenatal | SMN1 | ~100% | 2%-5% 5 | 95%-98% 6, 7 |
| Prognostic | SMN2 | NA | NA | See footnote 8. |
- 1.
See Table A. Genes and Databases for chromosome locus and protein.
- 2.
See Molecular Genetics for information on allelic variants detected in this gene.
- 3.
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
- 4.
Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative PCR and multiplex ligation-dependent probe amplification (MLPA) to detect single-exon deletions or duplications. Note that SMN1 and SMN2 are nearly identical; therefore, gene-targeted microarray cannot be used to determine SMN1 and SMN2 copy number.
- 5.
Detects the 2%-5% of individuals who are compound heterozygous for an intragenic pathogenic variant and an SMN1 deletion of at least exon 7 [Parsons et al 1998, Wirth 2000]
- 6.
Bussaglia et al [1995], Lefebvre et al [1995], Parsons et al [1996], Hahnen et al [1997], McAndrew et al [1997], Talbot et al [1997], Ogino & Wilson [2002]
- 7.
False negatives may occur because about 5%-8% of the population have two copies of SMN1 on a single chromosome and a deletion on the other chromosome, known as a [2+0] configuration. Individuals of sub-Saharan African heritage have a higher proportion of the [2+0] configuration [Verhaart et al 2017] (see Carrier Detection, Interpretation of the results of carrier testing).
- 8.
Note: Gene-targeted deletion/duplication analysis of SMN2 can be performed to provide additional phenotype information if the diagnosis of SMA is confirmed on molecular genetic testing. The number of copies of SMN2 may range from zero to five. Quantitative PCR and MLPA methods are often designed to detect both SMN1 and SMN2 copy number [Anhuf et al 2003, Arkblad et al 2006, Scarciolla et al 2006] (see Genotype-Phenotype Correlations).
Testing to determine carrier status is reviewed in Genetic Counseling.
Clinical Characteristics
Clinical Description
SMA is characterized by muscle weakness and atrophy resulting from progressive degeneration and irreversible loss of the anterior horn cells in the spinal cord (i.e., lower motor neurons) and the brain stem nuclei. The onset of weakness ranges from before birth to adulthood. The weakness is symmetric, proximal greater than distal, and progressive.
Before the advent of molecular diagnosis, attempts were made to classify SMA into discrete subtypes; however, it is now apparent that the phenotype of SMA associated with SMN1 pathogenic variants spans a broad continuum without clear delineation of subtypes. Newly approved treatment options (see Management, Treatment of Manifestations, Table 7) are changing the natural history of SMA phenotypes and blurring the boundaries even further [Tizzano & Finkel 2017]. Nonetheless, the existing classification system (Table 2) based on age of onset and maximum function attained with supportive care only is useful for prognosis and management.
Table 2.
Spectrum of SMA Phenotypes at Presentation
| Phenotype | Age of Onset | Life Span 1 | Motor Milestones 1 | Other Findings 1 |
|---|---|---|---|---|
| SMA 0 | Prenatal | A few weeks, <6 mos | None achieved |
|
| SMA I | <6 mos | Median survival 8-10 mos | Some head control, sit w/support only |
|
| SMA II | 6-18 mos | 70% alive at age 25 yrs | Independent sitting when placed |
|
| SMA III | >18 mos | Normal | Independent ambulation |
|
| SMA IV | Adulthood | Normal | Normal |
|
- 1.
With supportive care only
SMA 0 presents with severe weakness, hypotonia, and respiratory distress at birth. There may be a history of decreased in utero movements, joint contractures, and atrial septal defects. Infants with SMA type 0 have severe respiratory compromise/failure and, with supportive care only, rarely survive past age six months [Dubowitz 1999, MacLeod et al 1999]. There have not been any published reports of infants with SMA 0 who have been treated with nusinersen or gene therapy (see Table 7).
SMA I manifests as marked weakness and developmental motor regression before age six months. The mean age of symptom onset is 2.5 months [Lin et al 2015]. Infants may acquire head control and ability to roll, but quickly lose these abilities. With supportive care only, affected children do not achieve the ability to sit independently. Proximal, symmetric muscle weakness, lack of motor development with regression of motor function, reduced or absent deep tendon reflexes, and poor muscle tone are the major clinical manifestations. Mild contractures are often noted at the knees and, rarely, at the elbows.
With supportive care only, fasciculation of the tongue is seen in most but not all infants. While the muscles of the face are relatively spared at initial presentation, bulbar weakness is present in the neonatal period or during the first few months, and infants frequently have problems sucking or swallowing, leading to growth failure and recurrent aspiration. Weakness of the intercostal respiratory muscles with relative preservation of diaphragm musculature leads to characteristic "bell-shaped" chest and paradoxic respiration (abdominal breathing). The diaphragm is not involved until late in the course of disease. Cognitive function is normal. Severe symptomatic bradycardia has been noted in a study of the long-term survival of ventilator-dependent individuals with SMA I [Bach 2007].
With supportive care only, prospective studies of children with SMA I have shown median survival of 24 months [Oskoui et al 2007]; however, more recent studies have shown a median time to either death or >16 hours/day of ventilation of 8-13.5 months [Finkel et al 2014, Kolb et al 2017]. With proactive respiratory and nutritional supportive care, survival is improving [Grychtol et al 2018]. Promising new treatments are changing the natural history of SMA I, particularly when treatment is initiated before onset of symptoms (see Table 7).
SMA II usually manifests between ages six and 12 months; the mean age of symptom onset is 8.3 months [Lin et al 2015]. Although poor muscle tone may be evident at birth or within the first few months of life, individuals with SMA II may gain motor milestones slowly until about age five years. With supportive care only, the maximum motor milestone attained is the ability to sit independently when placed. Affected individuals then have a slow decline in motor function and on average lose the ability to sit independently by the mid-teens [Mercuri et al 2016]. Hand tremor is common. Deep tendon reflexes are decreased to absent. Scoliosis is common with progression of disease. Cognition is normal. Cardiac abnormalities are unlikely to develop [Finkel et al 2018]. Progressive respiratory muscle weakness leads to restrictive lung disease that is associated with morbidity and mortality in these individuals.
With supportive care only, the life expectancy of persons with SMA II is not known with certainty. A review of life expectancy of 240 individuals with SMA II from Germany and Poland found that 68% of individuals with SMA II were alive at age 25 years [Zerres et al 1997]. The ability to stand is directly correlated with better pulmonary function and long-term survival. This natural history, however, will likely be improved by newer treatments (see Table 7).
SMA III typically manifests after age 18 months with a mean age of onset of 39 months ± 32.6 months [Lin et al 2015]. The legs are more severely affected than the arms. With supportive care only, individuals walk independently but proximal muscle weakness may lead to more frequent falls or trouble walking up and down stairs. Fatigue can adversely affect quality of life and function significantly.
Most children with SMA III treated only with supportive care make gains in their motor function until about age six years and then experience a slow decline in function until about puberty. Puberty (until age ~20) may be associated with a more rapid decline in function for adolescents with SMA III.
With supportive care only, adulthood is then associated with another, much slower decline in function [Montes et al 2018]. Although individuals with SMA III develop the ability to walk, the vast majority will lose that ability with time. If symptom onset is before age three years, loss of ambulation typically occurs in the second decade. However, if symptom onset is between ages three and 12 years, loss of ambulation may occur in the fourth decade [Wadman et al 2017]. Individuals with SMA III have little to no respiratory muscle weakness. Cardiac and cognitive functions are normal. In a retrospective study of individuals with SMA, the life expectancy of 329 individuals with SMA III from Germany and Poland treated only with supportive care was not different from that of the general population [Zerres et al 1997]. This natural history, however, will likely be improved by newer treatments (see Table 7).
SMA IV typically presents with muscle weakness in the second or third decade of life. There is a specific pattern of muscle involvement, with weakness disproportionately affecting the deltoids, triceps, and quadriceps. There may be a loss of patellar reflexes, with sparing of the deep tendon reflexes in the upper extremities and Achilles. Individuals may have a hand tremor. Cardiac and cognitive functioning is normal. With supportive care only, findings are similar to but less severe than those described for SMA III, and if loss of ambulation occurs, it may be after the fifth decade [Brahe et al 1995, Clermont et al 1995, Zerres et al 1997, Wadman et al 2017]. Life expectancy is normal. SMA IV is the least common form of SMA and affects fewer than 5% of individuals with SMA [Kolb et al 2017].
Potential Complications of SMA
Poor weight gain with growth failure, restrictive lung disease, scoliosis, joint contractures, and sleep difficulties are common complications of SMA in those who receive supportive care only. At this time, it is unknown what long-term complications may arise in individuals who receive early and/or presymptomatic targeted treatment.
Nutrition/gastrointestinal
- Bulbar dysfunction is universal in individuals with SMA I; the bulbar dysfunction eventually becomes a serious problem for persons with SMA II and only very late in the course of disease for those with SMA III.
- Gastrointestinal issues may include constipation, delayed gastric emptying, and potentially life-threatening gastroesophageal reflux with aspiration.
- Growth failure can be addressed with gastrostomy tube placement as needed (see Management).
- Nonambulatory individuals with SMA II and III are at risk of developing obesity [Mercuri et al 2018].
Respiratory. Children with SMA I and II (and more rarely, type III) who are treated with supportive care only have progressive decline in pulmonary function due to a combination of weak respiratory muscles, reduced chest wall and lung compliance, and a reduction in alveolar multiplication [Chng et al 2003].
- Respiratory failure is the most common cause of death in SMA I and II.
- Decreased respiratory function leads to impaired cough with inadequate clearance of lower airway secretions, hypoventilation during sleep, and recurrent pneumonia.
- Noninvasive ventilation, such as BiPAP, and airway clearance techniques are commonly used to improve respiratory insufficiency in those with SMA (see Management).
Orthopedic. Scoliosis, hip dislocation, and joint contractures are common complications in individuals with SMA. Scoliosis is a major problem in most persons with SMA II and in half of those with SMA III. With supportive care only:
- Approximately 50% of affected children (especially those who are nonambulatory) develop spinal curvatures of more than 50 degrees (which require surgery) before age ten years;
- Later in the disease course, nonambulatory individuals can develop thoracic kyphosis [Mercuri et al 2018];
- Progressive scoliosis impairs lung function and if severe can cause decreased cardiac output [Chng et al 2003].
Use of the vertical expandable prosthetic titanium rib is a possible treatment for severe scoliosis (see Management).
Metabolic. An unexplained potential complication of SMA is severe metabolic acidosis with dicarboxylic aciduria and low serum carnitine concentrations during periods of intercurrent illness or prolonged fasting [Kelley & Sladky 1986].
- Whether these metabolic abnormalities are primary or secondary to the underlying defect in SMA is unknown.
- Although the etiology of these metabolic derangements remains unknown, one report suggests that aberrant glucose metabolism may play a role [Bowerman et al 2012].
- Prolonged fasting should be avoided (see Agents/Circumstances to Avoid).
Prognosis
The availability of new targeted treatment options (see Table 7) will likely change the natural history of this condition. Furthermore, diagnosis prior to symptom onset through newborn screening programs, coupled with targeted therapies, will likely decrease the morbidity and mortality regardless of treatment strategy.
Genotype-Phenotype Correlations
SMN1. No correlation exists between the type of SMN1 pathogenic variants and the severity of disease: the homozygous exon 7 deletion is observed with approximately the same frequency in all phenotypes.
SMN2. Small amounts (up to a quarter) of full-length transcripts generated by SMN2 produce functional protein and result in the milder SMA II or SMA III phenotype. The number of copies (dosage) of SMN2 (arranged in tandem in cis configuration on each chromosome) ranges from zero to five (see Molecular Genetics). The presence of two copies of SMN2 is approximately 80% predictive of the SMA I phenotype, whereas the presence of four or more copies of SMN2 is approximately 88% predictive of achieving the ability to ambulate with supportive care only (SMA III/IV) [Calucho et al 2018]. Modifying factors that are not fully understood are likely to contribute to the variability in clinical severity, as can be easily demonstrated with individuals who have three copies of SMN2. Data from Calucho et al [2018] are summarized in Table 3.
Table 3.
SMN2 Copy Number and SMA Clinical Phenotype
| SMN2 Copy Number | SMA Clinical Phenotype 1 | ||
|---|---|---|---|
| SMA I | SMA II 2 | SMA III/IV 3 | |
| 1 | 96% | 4% | 0% |
| 2 | 79% | 16% | 5% |
| 3 | 15% | 54% | 31% |
| >=4 4 | 1% | 11% | 88% |
Adapted from Calucho et al [2018]
- 1.
Clinical phenotype with supportive care only
- 2.
With supportive care only, the maximum motor function achieved is sitting.
- 3.
With supportive care only, ambulation is achieved but may not be maintained.
- 4.
Prior et al [2004] reported three asymptomatic, unrelated individuals homozygous for an SMN1 deletion who had five copies of SMN2, demonstrating that expression levels consistent with five copies of SMN2 may compensate for the lack of SMN1 expression.
Other putative modifiers of SMA phenotype
- A single-base substitution – c.859G>C (p.Gly287Arg) – in exon 7 of SMN2 has been identified as a disease modifier resulting in a milder disease [Prior et al 2009]. This substitution creates a new exon splicing enhancer (ESE) element. The new ESE increased the amount of exon 7 inclusion and number of full-length transcripts generated from SMN2.
- In some rare families with unaffected females who have biallelic SMN1 deletions, the expression of plastin 3 (encoded by PLS3 at chromosome locus Xq23) was higher than in their SMA-affected counterparts. PLS3 was shown to be important for axonogenesis and therefore may act as a protective modifier [Oprea et al 2008].
Nomenclature
SMA I was previously known as Werdnig-Hoffmann disease or acute SMA [Hoffmann 1892, Werdnig 1971].
SMA II was called chronic SMA or Dubowitz disease prior to the current classification.
SMA III has had the eponym "Kugelberg-Welander disease" and has also been referred to as juvenile SMA [Kugelberg & Welander 1956].
SMA IV may also be referred to as adolescent- or adult-onset SMA.
Prevalence
The exact prevalence of SMA is unknown. Historical studies evaluating the prevalence of SMA were limited by lack of genetic confirmation and may underestimate the prevalence of more severe phenotypes due to the shortened life span. It has been suggested that the overall prevalence of SMA is between one and two per 100,000 people [Verhaart et al 2017]. In regions or groups with high consanguinity rates, the incidence of SMA can be higher.
Table 4.
Carrier Frequency and Incidence of SMA
| Population | Carrier Frequency | Estimated Incidence |
|---|---|---|
| Arab | 1:59 | Not reported |
| Asian | 1:48 | 1:8009 |
| Asian Indian | 1:71 | 1:9655 |
| Black (sub-Saharan African heritage) | 1:100 | 1:18,808 |
| White | 1:45 | 1:7829 |
| Hispanic | 1:77 | 1:20,134 |
| Jewish | 1:56 | 1:10,000 |
Adapted from Verhaart et al [2017]
Differential Diagnosis
Table 5.
Disorders to Consider in the Differential Diagnosis of Spinal Muscular Atrophy (SMA)
| Age of Onset | Disorder | Gene(s) or Region | MOI | Clinical Features of Differential Diagnosis Disorder | |
|---|---|---|---|---|---|
| Overlapping w/SMA | Distinguishing from SMA | ||||
| Congenital to <6 mos | X-linked infantile SMA | UBA1 | XL | Hypotonia, weakness, areflexia | |